Literature DB >> 15804677

A self-administered questionnaire to measure cigarette withdrawal symptoms: the Cigarette Withdrawal Scale.

Jean-François Etter1.   

Abstract

Because few tobacco withdrawal scales have been submitted to appropriate validity analyses, we sought to develop and assess the validity of a new, self-administered scale measuring cigarette withdrawal symptoms. We generated the instrument content by conducting a qualitative survey of 404 smokers and ex-smokers. Then we tested 61 items on the Internet in 3,050 smokers and ex-smokers. Subsamples provided comprehensive retest data after 17 days (n = 1218) and smoking status after 41 days (n = 673). The study resulted in a 21-item, six-dimension scale labeled the Cigarette Withdrawal Scale (CWS-21). The six subscales cover the main components of nicotine or tobacco withdrawal in the Diagnostic and Statistical Manual of Mental Disorders and International Statistical Classification of Diseases and Related Health Problems and in qualitative data: Depression-anxiety, craving, irritability-impatience, appetite-weight gain, insomnia, and difficulty concentrating. The six scores had a satisfactory test-retest reliability (r = .60-.71) and a high internal consistency (Cronbach's alpha = .83-.96). The factor structure of the scale was robust in a bootstrap resampling procedure. In ex-smokers, all scores except appetite-weight gain and insomnia predicted relapse at 41-day follow-up. In recent ex-smokers who had quit smoking less than 14 days before baseline, all scores except appetite-weight gain decreased between baseline and the 17-day retest. In baseline ex-smokers who relapsed to smoking at the 17-day retest, appetite-weight gain decreased and craving increased between baseline and retest. CWS-21 is a reliable, valid, multidimensional measure of cigarette withdrawal symptoms that is sensitive to change over time and predicts relapse to smoking.

Entities:  

Mesh:

Year:  2005        PMID: 15804677     DOI: 10.1080/14622200412331328501

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  18 in total

1.  Reliability of striatal [¹¹C]raclopride binding in smokers wearing transdermal nicotine patches.

Authors:  Karmen K Yoder; Daniel S Albrecht; David A Kareken; Lauren M Federici; Kevin M Perry; Elizabeth A Patton; Qi-Huang Zheng; Bruce H Mock; Sean J O'Connor; Christine M Herring
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-19       Impact factor: 9.236

2.  Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures?

Authors:  Robert West; Michael Ussher
Journal:  Psychopharmacology (Berl)       Date:  2009-12-22       Impact factor: 4.530

3.  Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales.

Authors:  Robert West; Michael Ussher; Mari Evans; Mamun Rashid
Journal:  Psychopharmacology (Berl)       Date:  2005-11-25       Impact factor: 4.530

4.  Test-retest variability of [¹¹C]raclopride-binding potential in nontreatment-seeking alcoholics.

Authors:  Karmen K Yoder; Daniel S Albrecht; David A Kareken; Lauren M Federici; Kevin M Perry; Elizabeth A Patton; Qi-Huang Zheng; Bruce H Mock; Sean O'Connor; Christine M Herring
Journal:  Synapse       Date:  2010-12-08       Impact factor: 2.562

5.  A novel stress-based intervention reduces cigarette use in non-treatment seeking smokers.

Authors:  Alexandra Barnabe; Karine Gamache; João Vitor Paes de Camargo; Erin Allen-Flanagan; Mathilde Rioux; Jens Pruessner; Marco Leyton; Karim Nader
Journal:  Neuropsychopharmacology       Date:  2022-09-29       Impact factor: 8.294

6.  Association of tobacco dependence and quit attempt duration with Rasch-modeled withdrawal sensitivity using retrospective measures.

Authors:  Harold S Javitz; Janet Brigham; Christina N Lessov-Schlaggar; Ruth E Krasnow; Gary E Swan
Journal:  Addiction       Date:  2009-06       Impact factor: 6.526

7.  A placebo-controlled trial of modafinil for nicotine dependence.

Authors:  Robert A Schnoll; E Paul Wileyto; Angela Pinto; Frank Leone; Peter Gariti; Steven Siegel; Kenneth A Perkins; Charles Dackis; Daniel F Heitjan; Wade Berrettini; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2008-06-09       Impact factor: 4.492

8.  Effects of smoking on D₂/D₃ striatal receptor availability in alcoholics and social drinkers.

Authors:  Daniel S Albrecht; David A Kareken; Karmen K Yoder
Journal:  Brain Imaging Behav       Date:  2013-09       Impact factor: 3.978

9.  Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers.

Authors:  Peter H Silverstone; Rana Dadashova
Journal:  Ann Gen Psychiatry       Date:  2012-03-09       Impact factor: 3.455

10.  Smoking reduction interventions for smoking cessation.

Authors:  Nicola Lindson; Elias Klemperer; Bosun Hong; José M Ordóñez-Mena; Paul Aveyard
Journal:  Cochrane Database Syst Rev       Date:  2019-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.